PlusCBD™ Oil Roll-On establish at 945 Kroger shops in 17 U.S. States
LAS VEGAS, NEVADA, June 12, 2019 (WORLD NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent provider and maker of hemp CBD products, is very happy to announce further expansion of the industry-dominating PlusCBD™ Oil brand name because of the Kroger Co. (NYSE:KR).
The Company’s expanded distribution that is retail the launch of CV Sciences’ new PlusCBD Oil™ Roll-Ons in 945 Kroger shops across several of its retail banners, including Kroger, Dillons, Fry’s, Fred Meyer, King Sooper, Mariano’s, Pick ‘n Save, QFC and Smiths areas in 17 U.S. states. PlusCBD™ Oil Roll-On, available in 200mg CBD and further Strength 500mg formulations, is infused with concentrated CBD from agricultural hemp plant parts, warming camphor and menthol that is cooling. Made with its Gold Formula focused complete range hemp extract, the Roll-Ons offer high strength help in a easy-to-use application. The Company’s best-selling PlusCBD™ Oil Extra Strength and Original Balms may also be available at the participating Kroger areas. All PlusCBD™ Oil topical products contain no phthalates, sulfates or parabens and are made without artificial dyes or scents to meet consumer expectations of clean ingredients.
As talked about regarding the Company’s very first quarter 2019 profits turn to May 8, 2019, CV Sciences’ recent distribution gains consist of accessibility to PlusCBD™ Oil Extra Strength Balm in a preliminary launch at CVS Pharmacy shops. By adding 945 Kroger places and distribution that is new other leading Food, Drug and Mass (FDM) stores, at the time of June 12, 2019, PlusCBD™ Oil branded products are for sale in 4,591 shops, up from 3,308 retail stores at the time of March 31, 2019, a growth of 38.7% throughout the previous 2 months.
“We are happy to partner with Kroger and introduce our Roll-On that is new topical we continue our fast expansion to the FDM channel,” said Joseph Dowling, ceo. “Kroger, CVS Pharmacy, and other leading nationwide retailers are keenly conscious of the increased customer need for hemp-based CBD items and they are partnering with CV Sciences because of our unwavering dedication to safety and quality. We are at the start of that which we think may be broad acceptance of CBD products across national FDM reports therefore we enjoy our continued development once we expand shop count and SKUs with your retail lovers.”
PlusCBD™ Oil Extra Strength Balm ranks #1 in product sales both in the U.S. that is total Natural and complete U.S. MULO (Multi Outlet) throughout the last 52 months* among CBD services and products within Topical Analgesics cbd oil, according to SPINS and IRI information, correspondingly. Brightfield Group, a number one predictive analytics and market research company for the CBD market, expects $1.3 billion in product sales of CBD topicals in 2019, with an ingredient growth that is annual of 169% from 2018 – 2022.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two business that is distinct: a consumer product unit centered on production, advertising and selling plant-based CBD items to a selection of market sectors; and a medication development unit focused on developing and commercializing CBD-based novel therapeutics utilizing CBD. The Company’s PlusCBD™ Oil may be the top-selling model of hemp-derived CBD available on the market, according to SPINS, the key provider of syndicated data and insights when it comes to normal, natural and specialty services and products industry. CV Sciences, Inc. has offices that are primary facilities in north park, Ca and nevada, Nevada. More information can be obtained from OTCMarkets.com or by visiting www.cvsciences.com.
This press release may include particular statements that are forward-looking information, as defined inside the concept of Section 27A for the Securities Act of 1933 and Section 21E of this Securities Exchange Act of 1934, and it is susceptible to the secure Harbor developed by those parts. This material contains statements about anticipated events that are future monetary outcomes which are forward-looking in general and susceptible to dangers and uncertainties. Such forward-looking statements by meaning incorporate risks, uncertainties.